Croda commits to Science Based Targets for reduction of greenhouse gas emissions
Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
Croda International has announced its commitment to reduce its greenhouse gas emissions in line with the Science Based Targets initiative.
Croda is one of the few companies within the speciality chemicals sector to commit to Science Based Targets (SBT), with the aim of restricting global warming to 1.5 °C above the pre-industrial average. With reductions in greenhouse gas emissions (GHG) a priority, Croda has already established Group targets to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
With more than 60% of the company’s raw materials already coming from bio-based sources, Croda believes that that they are well positioned to not only reduce their GHG emissions, but to become ‘Climate Positive’. This ambitious target will focus on the use of more bio-based raw materials, and also through the ongoing work that Croda is undertaking to quantify the carbon savings derived from their products as they are used by their customers and the end consumers. In 2018, over 700,000 tonnes of GHG emissions were avoided through just four of Croda’s products in application. For example, Croda’s Coltide RadianceTM extends the lifetime of clothes, avoiding additional carbon and water intensive manufacture.
Terry Thistlethwaite, Vice President of Sustainability at Croda said: “We are proud to be one of around 600 companies taking science-based climate action and reducing greenhouse gas emissions by committing to Science Based Targets.
"Our business purpose is to use Smart Science to Improve Lives; this is just one area where we are pushing ourselves and supporting our customers to have a positive impact on the planet and society. We will continue to lead the speciality chemicals industry with our approach to sustainability.”
The Science Based Targets initiative is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). It signals an acceleration in the transition to a low carbon economy and supports companies who are already demonstrating they have the skills, expertise and ingenuity to make this a reality.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance